Frank Ruffo Biography and Net Worth

Frank Ruffo co-founded Aclaris and has served as Chief Financial Officer since its inception in 2012.

He is a senior financial executive with more than 25 years of biotech and specialty pharmaceutical management expertise in early stage through fully commercial operations. From 2014 to 2015, Frank served part time as a financial consultant at Ralexar Therapeutics, Inc. (formerly known as Alexar Therapeutics Inc.), a specialty dermatology company. Frank also served part time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining Aclaris, Frank co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan in 2011. Prior to joining Vicept Therapeutics, from 1996 to 2008 he served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc.

Frank is a certified public accountant in Pennsylvania (inactive since 2008). He received his Bachelor of Science in business administration with a major in accounting from La Salle University.

What is Frank Ruffo's net worth?: The estimated net worth of Frank Ruffo is at least $257,142.57 as of April 22nd, 2021. Mr. Ruffo owns 209,059 shares of Aclaris Therapeutics stock worth more than $257,143 as of April 19th. This net worth evaluation does not reflect any other investments that Mr. Ruffo may own. Learn More about Frank Ruffo's net worth.
How do I contact Frank Ruffo?: The corporate mailing address for Mr. Ruffo and other Aclaris Therapeutics executives is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. Aclaris Therapeutics can also be reached via phone at (484) 324-7933 and via email at [email protected]. Learn More on Frank Ruffo's contact information.
Has Frank Ruffo been buying or selling shares of Aclaris Therapeutics?: Frank Ruffo has not been actively trading shares of Aclaris Therapeutics in the last ninety days. Most recently, Frank Ruffo sold 12,823 shares of the business's stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $15.55, for a transaction totalling $199,397.65. Learn More on Frank Ruffo's trading history.
Who are Aclaris Therapeutics' active insiders?: Aclaris Therapeutics' insider roster includes Kamil Ali-Jackson (Insider), David Gordon (Insider), Joseph Monahan (Insider), Frank Ruffo (CFO), and Neal Walker (CEO). Learn More on Aclaris Therapeutics' active insiders.
Are insiders buying or selling shares of Aclaris Therapeutics?: During the last year, Aclaris Therapeutics insiders bought shares 1 times. They purchased a total of 14,705 shares worth more than $99,994.00. During the last year, insiders at the biotechnology company sold shares 3 times. They sold a total of 18,000 shares worth more than $136,080.00. The most recent insider tranaction occured on October, 23rd when insider Joseph Monahan sold 6,000 shares worth more than $30,480.00. Insiders at Aclaris Therapeutics own 5.5% of the company. Learn More about insider trades at Aclaris Therapeutics.
Information on this page was last updated on 10/23/2023.

Frank Ruffo Insider Trading History at Aclaris Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/10/2022	Sell	12,823	$15.55	$199,397.65
4/26/2021	Sell	27,339	$25.80	$705,346.20	209,059
4/22/2021	Sell	30,000	$26.84	$805,200.00	209,059
5/7/2018	Buy	1,250	$18.22	$22,775.00	156,865
4/6/2018	Buy	1,250	$16.59	$20,737.50	155,615

Frank Ruffo Buying and Selling Activity at Aclaris Therapeutics

Aclaris Therapeutics Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Today's Range

Now: $1.25

$1.21

$1.25

50 Day Range

MA: $1.22

$1.15

$1.44

2 Week Range

Now: $1.25

$0.59

$11.12

Volume

445,508 shs

Average Volume

1,531,810 shs

Market Capitalization

$88.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story